1-(3-Fluoro-4-(5-methyl-6-(2-(4-methylpiperazin-1-yl)ethoxy)pyrrolo[2,1-f][1,2,4] triazin-4-yloxy)phenyl)-3-(2-(4-fluorophenyl)acetyl)thiourea, bis-hydrochloride salt → 1-Cyclopropanecarbonyl-3-(3-fluoro-4-(5-methyl-6-(2-(4-methylpiperazin-1-yl)ethoxy)pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)phenyl)urea

Participants

Reaction Steps

Prepared in a similar manner as Example 264 using Compound B of Example 45 and Compound A of Example 280 (20.3 mg, 64%). 1H NMR (CD3OD) δ 10.85 (s, 1H), 7.70 (s, 1H), 7.76–7.72 (m, 2H), 7.22–7.14 (m, 2H), 4.14 (t, 2H, J=5.5 Hz), 2.94 (t, 2H, J=5.5 Hz), 2.89–2.60 (m, 4H), 2.78 (s, 3H), 2.34 (s, 4H), 1.70–1.67 (m, 1H), 0.99–0.95 (m, 2H), 0.91–0.86 (m, 2H); MS(ESI+) m/z 512.3 (M+H)+.

Provenance & Evidence